États-Unis · Plateformes & données · MarketBeat

What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call

Publié par MarketBeat · États-Unis il y a 2 h

Travere Therapeutics (NASDAQ:TVTX) reported third-quarter results marked by record FILSPARI sales, continued early adoption in focal segmental glomerulosclerosis (FSGS), and…

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call

À lire aussi

Clorox forecasts 3.5%-4.5% organic sales growth as input cost inflation rises to $240M

JAKKS Pacific: 3 Key Takeaways for Long-Term Investors

Apple’s iPhone business is booming. Here’s why the stock is falling anyway.

Disney eyes thousands of layoffs, asks managers to target 20% savings, Bloomberg News reports

Stock market after midterm elections: What S&P 500 history shows

Locksley Resources Options Expire Without Exercise

What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call

Partager

À lire aussi

Clorox forecasts 3.5%-4.5% organic sales growth as input cost inflation rises to $240M

JAKKS Pacific: 3 Key Takeaways for Long-Term Investors

Apple’s iPhone business is booming. Here’s why the stock is falling anyway.

Disney eyes thousands of layoffs, asks managers to target 20% savings, Bloomberg News reports

Stock market after midterm elections: What S&P 500 history shows

Locksley Resources Options Expire Without Exercise